INBX vs INMB

Inhibrx Biosciences, Inc. vs INmune Bio Inc. — Valuation Comparison 2026

INBX

Biotechnology
Inhibrx Biosciences, Inc.
Quality
5.3
out of 10
Value Trap
8
SAFE
Price
$103.98
Last close
Models
8/13
Active
VS

INMB

Biotechnology
INmune Bio Inc.
Quality
5.7
out of 10
Value Trap
26
LOW
Price
$1.42
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType INBX Fair ValueINBX Upside INMB Fair ValueINMB Upside
Bayesian DCF Intrinsic $28.69 -72.4% $0.57 -59.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.89 -97.2% $1.90 +34.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for INBX vs INMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INBX vs INMB — Which Stock Is More Undervalued?

INMB scores higher with a 5.7/10 quality rating vs INBX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Inhibrx Biosciences, Inc. (INBX) and INmune Bio Inc. (INMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INBX currently trades at $103.98 with a QOC of 5.3/10, while INMB trades at $1.42 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).